Cancer- The breaking news on the treatment, cure and diagnosis of cancer

 
 

 
 

  • Search for "cancer news"

  • Lapatinib Combined With Cetuximab Overcomes Resistance In EGFR-Driven Tumors

    Lapatinib Combined With Cetuximab Overcomes Resistance In EGFR-Driven Tumors
    Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy.

  • Positive Survival Trend Seen In Phase I Study Of Temsirolimus, Capecitabine

    Positive Survival Trend Seen In Phase I Study Of Temsirolimus, Capecitabine
    A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients.

  • More Genes Discovered In The Fight Against Breast Cancer

    More Genes Discovered In The Fight Against Breast Cancer
    In a study published in Nature , researchers describe nine new genes that drive the development of breast cancer.

  • Minimal Residual Disease Detected In Nearly Double The Number Of...

    Minimal Residual Disease Detected In Nearly Double The Number Of...
    A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal ... (more)

  • Established Cancer Vaccine Works Better In Tandem With FDA-Approved Kidney Transplant Drug

    Established Cancer Vaccine Works Better In Tandem With FDA-Approved Kidney Transplant Drug
    A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab.
  • Biocompare Cancer

  • Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors Helps Personalize Treatment

    Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors Helps Personalize Treatment
    NEW YORK, May 16, 2012 - Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas - the most common type of non-small cell lung cancer - and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma.

  • Researchers Make Promising Discovery In Pursuit Of Effective Lymphoma Treatments

    Researchers Make Promising Discovery In Pursuit Of Effective Lymphoma Treatments
    NEW YORK, May 16, 2012 - Researchers at NYU School of Medicine have identified a target for slowing the progression of multiple myeloma by using currently available drugs.

  • Finnish Researchers Identified The Cause For LGL Leukemia

    Finnish Researchers Identified The Cause For LGL Leukemia
    LGL leukemia is a relatively rare, malignant blood disease of the mature T-cells and, in many cases, it is related to autoimmune diseases such as rheumatoid arthritis. The pathogenetic mechanism of the disease has been unknown and it has previously been unclear if the disease is an overreaction of the normal defense system or a malignant hematological disease.

  • FDA-Approved Drug Makes Established Cancer Vaccine Work Better

    FDA-Approved Drug Makes Established Cancer Vaccine Work Better
    PHILADELPHIA - A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab. This proof-of-concept study is published this week in Science Translational Medicine. Senior authors of the study are Robert H. Vonderheide, MD, DPhil, associate professor of Medicine, and James Riley, PhD, associate professor of Microbiology.

  • Predicting Cancer Relapse: Study Finds High-Throughput Sequencing Bests Flow Cytometry

    Predicting Cancer Relapse: Study Finds High-Throughput Sequencing Bests Flow Cytometry
    SEATTLE - A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease. The results of the study, led by Hutchinson Center computational biologist Harlan Robins, Ph.D., are reported in the May 16 issue of Science Translational Medicine.